Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.62
ROSG's Cash-to-Debt is ranked higher than
64% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ROSG: 1.62 )
Ranked among companies with meaningful Cash-to-Debt only.
ROSG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.77  Med: 62.38 Max: No Debt
Current: 1.62
Equity-to-Asset 0.37
ROSG's Equity-to-Asset is ranked higher than
66% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ROSG: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
ROSG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.27  Med: 0.7 Max: 0.95
Current: 0.37
-0.27
0.95
Piotroski F-Score: 2
Altman Z-Score: -21.12
WACC vs ROIC
4.70%
-364.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -169.64
ROSG's Operating Margin % is ranked lower than
77% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ROSG: -169.64 )
Ranked among companies with meaningful Operating Margin % only.
ROSG' s Operating Margin % Range Over the Past 10 Years
Min: -9864.67  Med: -3704.25 Max: -169.63
Current: -169.64
-9864.67
-169.63
Net Margin % -175.80
ROSG's Net Margin % is ranked lower than
77% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ROSG: -175.80 )
Ranked among companies with meaningful Net Margin % only.
ROSG' s Net Margin % Range Over the Past 10 Years
Min: -11003.33  Med: -4193.47 Max: -175.8
Current: -175.8
-11003.33
-175.8
ROE % -132.15
ROSG's ROE % is ranked lower than
87% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ROSG: -132.15 )
Ranked among companies with meaningful ROE % only.
ROSG' s ROE % Range Over the Past 10 Years
Min: -545.27  Med: -84.49 Max: -47.3
Current: -132.15
-545.27
-47.3
ROA % -98.90
ROSG's ROA % is ranked lower than
87% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ROSG: -98.90 )
Ranked among companies with meaningful ROA % only.
ROSG' s ROA % Range Over the Past 10 Years
Min: -240.7  Med: -81.02 Max: -40.87
Current: -98.9
-240.7
-40.87
ROC (Joel Greenblatt) % -376.10
ROSG's ROC (Joel Greenblatt) % is ranked lower than
73% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ROSG: -376.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ROSG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1452.9  Med: -922.18 Max: -202.49
Current: -376.1
-1452.9
-202.49
3-Year Revenue Growth Rate 118.60
ROSG's 3-Year Revenue Growth Rate is ranked higher than
97% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ROSG: 118.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ROSG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.65 Max: 129.7
Current: 118.6
0
129.7
3-Year EBITDA Growth Rate -18.30
ROSG's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ROSG: -18.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ROSG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -69.5  Med: -23.6 Max: -7.7
Current: -18.3
-69.5
-7.7
3-Year EPS without NRI Growth Rate -17.30
ROSG's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ROSG: -17.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ROSG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.9  Med: -29.45 Max: 3.5
Current: -17.3
-68.9
3.5
GuruFocus has detected 5 Warning Signs with Rosetta Genomics Ltd $ROSG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ROSG's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:OTCPK:VRTT, NAS:ATOS, OTCPK:BMKDF, OTCPK:BTHCF, OTCPK:MTST, OTCPK:IMEXF, OTCPK:ETAH, OTCPK:OXIS, OTCPK:LEDIF, OTCPK:DIGP, OTCPK:MCUIF, OTCPK:GBSN, OTCPK:BZYR, OTCPK:JFIL, OTCPK:TBIO, OTCPK:EXDI, OTCPK:MDIT, NAS:TEAR, OTCPK:CRRVF, OTCPK:MHTX » details
Traded in other countries:RQ1.Germany,
Headquarter Location:Israel
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic products based on a recently discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA.

Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Ratios

vs
industry
vs
history
PB Ratio 0.70
ROSG's PB Ratio is ranked higher than
98% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ROSG: 0.70 )
Ranked among companies with meaningful PB Ratio only.
ROSG' s PB Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.25 Max: 31.74
Current: 0.7
0.46
31.74
PS Ratio 0.32
ROSG's PS Ratio is ranked higher than
95% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ROSG: 0.32 )
Ranked among companies with meaningful PS Ratio only.
ROSG' s PS Ratio Range Over the Past 10 Years
Min: 0.3  Med: 28.2 Max: 210.66
Current: 0.32
0.3
210.66
EV-to-EBIT -0.12
ROSG's EV-to-EBIT is ranked higher than
99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ROSG: -0.12 )
Ranked among companies with meaningful EV-to-EBIT only.
ROSG' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.4  Med: -0.6 Max: 0.3
Current: -0.12
-12.4
0.3
EV-to-EBITDA -0.12
ROSG's EV-to-EBITDA is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ROSG: -0.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
ROSG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.4  Med: -0.6 Max: 0.3
Current: -0.12
-12.4
0.3
Current Ratio 2.50
ROSG's Current Ratio is ranked higher than
54% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ROSG: 2.50 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 6.49 Max: 25.08
Current: 2.5
0.65
25.08
Quick Ratio 2.50
ROSG's Quick Ratio is ranked higher than
60% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ROSG: 2.50 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 6.49 Max: 25.08
Current: 2.5
0.65
25.08
Days Sales Outstanding 112.69
ROSG's Days Sales Outstanding is ranked lower than
81% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ROSG: 112.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.47  Med: 136.25 Max: 885.73
Current: 112.69
27.47
885.73
Days Payable 77.23
ROSG's Days Payable is ranked higher than
55% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ROSG: 77.23 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 62.27  Med: 562.16 Max: 1066.71
Current: 77.23
62.27
1066.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.10
ROSG's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ROSG: -28.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ROSG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -236.2  Med: -66.2 Max: 0
Current: -28.1
-236.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 1.57
ROSG's Price-to-Net-Current-Asset-Value is ranked higher than
98% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ROSG: 1.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ROSG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.34  Med: 1.7 Max: 5.01
Current: 1.57
1.34
5.01
Price-to-Tangible-Book 0.71
ROSG's Price-to-Tangible-Book is ranked higher than
98% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ROSG: 0.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ROSG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.7  Med: 1.57 Max: 3.68
Current: 0.71
0.7
3.68
Price-to-Intrinsic-Value-Projected-FCF 0.85
ROSG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ROSG: 0.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ROSG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.84  Med: 2.09 Max: 8.64
Current: 0.85
0.84
8.64
Price-to-Median-PS-Value 0.01
ROSG's Price-to-Median-PS-Value is ranked higher than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ROSG: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ROSG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.18 Max: 5.58
Current: 0.01
0.01
5.58
Earnings Yield (Greenblatt) % -791.32
ROSG's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ROSG: -791.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ROSG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1169.9  Med: 1640.4 Max: 10214.4
Current: -791.32
-1169.9
10214.4

More Statistics

Revenue (TTM) (Mil) $9.23
EPS (TTM) $ -9.31
Beta0.62
Short Percentage of Float3.52%
52-Week Range $1.40 - 18.60
Shares Outstanding (Mil)2.59

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 18 23
EPS ($) -5.64 -3.96 -2.16
EPS without NRI ($) -5.64 -3.96 -2.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics Focusing Efforts on Improving Cash Position through Sale of the PersonalizeDx... May 22 2017
Rosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal(TM)... May 12 2017
Rosetta Genomics Expands International Access for RosettaGX Reveal(TM) through Agreement with... May 05 2017
Rosetta Genomics Receives Final Approval from New York State for First-of-its-kind Thyroid Cancer... May 04 2017
Rosetta Genomics to Increase Investment in RosettaGX Reveal(TM) and Explore Strategic Alternatives... May 02 2017
Rosetta Genomics Expands Patent Portfolio in Europe and Japan May 01 2017
New Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary... Apr 27 2017
Edited Transcript of ROSG earnings conference call or presentation 30-Mar-17 2:00pm GMT Mar 30 2017
Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results Mar 30 2017
Rosetta Genomics to Host 2016 Fourth Quarter and Year End Financial Results and Business Update... Mar 23 2017
Rosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay Mar 20 2017
Rosetta Genomics Announces 1-for-12 Reverse Stock Split Mar 16 2017
Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible... Feb 23 2017
Rosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth... Feb 08 2017
Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs Feb 06 2017
Rosetta Genomics Reports Third Quarter 2016 Financial Results Dec 20 2016
Rosetta Genomics to Present at the 9th Annual LD Micro Main Event Dec 01 2016
Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement... Nov 23 2016
Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to... Nov 21 2016
Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat